Nasdaq Extends Deadline for CombiMatrix to Meet Listing Requirement | GenomeWeb

NEW YORK (GenomeWeb News) – Nasdaq has granted CombiMatrix an extension to provide evidence that it is in compliance with a listing requirement, the company said in a regulatory document on Thursday.

In a filing with the US Securities and Exchange Commission, CombiMatrix said that Nasdaq has given it until Aug. 20 to provide evidence in its Form 10-Q for the second quarter ending June 30 that it complies with a rule calling for at least $2.5 million in stockholders' equity in order to remain listed on the exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.